Blood-derived topical therapy for ocular surface diseases

Area of Science:

• Ophthalmology
• Regenerative Medicine
• Biologics

Background:

• Human serum and plasma-derived therapies are increasingly used for ocular surface disorders.
• Evidence supports their safety and efficacy for conditions like dry eye syndrome and persistent epithelial defects.
• Current limitations include the costly and inconvenient procurement of blood-derived products.

Purpose of the Study:

• To review the existing literature on the safety and efficacy of blood-derived products for ocular surface diseases.
• To discuss the production challenges and potential solutions for autologous serum tears.
• To explore alternative blood-derived therapies like umbilical cord serum and platelet-derived plasma.

Main Methods:

• Literature review of scientific and clinical studies.
• Analysis of safety and efficacy data for various blood-derived ocular therapies.
• Discussion of production methods and accessibility issues.

Main Results:

• Autologous serum tears demonstrate good safety and efficacy for ocular surface conditions.
• Alternative therapies like umbilical cord serum and platelet-derived plasma offer potential for wider availability.
• Production of autologous serum tears presents challenges that need addressing for broader clinical adoption.

Conclusions:

• Blood-derived therapies are valuable options for managing ocular surface disorders.
• Improving the accessibility and production of these therapies is crucial for wider patient benefit.
• Further research into novel blood-derived preparations may enhance treatment outcomes.